Bavarian Nordic shares sink by 12% after mpox sales slump in Q3
Revenue for the mpox vaccine is down compared to last year however its travel vaccine business grew by 21%.
Revenue for the mpox vaccine is down compared to last year however its travel vaccine business grew by 21%.
What's Your Reaction?
